NCT06299163终止1 期
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 11
- 主要终点
- Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0 / ASTCT (for Cytokine Release Syndrome [CRS])
研究概览
简要总结
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed, advanced-stage protocol-specified solid tumors.
- •Confirmed ROR1 tumor expression.
- •Patients who have undergone at least one prior systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable or have medical contraindications to standard therapy.
排除标准
- •Prior treatment with any agent targeting ROR1 or prior treatment with a CD3 T-cell engaging therapy.
- •Prior treatment with chimeric antigen receptor (CAR) cell therapy within 90 days prior to first dose of NM32-
- •Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of NM32-
- •Wide-field radiotherapy (> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of NM32-2668, or no recovery from side effects of such prior interventions.
研究组 & 干预措施
NM32-2668
Experimental
干预措施: NM32-2668 (Biological)
结局指标
主要结局
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0 / ASTCT (for Cytokine Release Syndrome [CRS])
时间窗: Through 50 days post-final dose administration
Incidence of Dose Limiting Toxicities (DLTs)
时间窗: Through 28 days post-infusion
Frequency of dose interruptions/reductions
时间窗: Up to 12 treatment cycles or through treatment discontinuation, whichever occurs first
Duration of dose interruptions/reductions
时间窗: Up to 12 treatment cycles or through treatment discontinuation, whichever occurs first
次要结局
- Assessment of the terminal phase (apparent elimination) rate constant (λz)(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Assessment of the area under the serum concentration-time curve extrapolated from the last quantifiable concentration to infinity (AUC[0-infinity])(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Incidence of specific ADAs by category to NM32-2668(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Progression-free Survival (PFS) according to RECIST 1.1(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment))
- Duration of Response (DOR) according to RECIST 1.1(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed through study completion (on average, 1 year after last treatment))
- Assessment of the the minimum observed serum concentration (Cmin)(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Assessment of the elimination half-life (t½)(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Time from dosing at which maximum observed serum concentration is apparent (Tmax)(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Disease Control Rate (DCR) according to RECIST 1.1(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed for up to 30 days following last dose of study treatment)
- Overall Survival (OS)(From date of randomization until the date of death from any cause, assessed through study completion (on average, 1 year after last treatment))
- Assessment of the maximum observed serum concentration (Cmax)(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Assessment of the volume of distribution (Vd) of NM32-2668 in serum(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Assessment of accumulation ratios of Cmax (ARcmax) of NM32-2668 in serum(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Frequency of specific anti-drug antibodies (ADAs) to NM32-2668(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Concentration of specific ADAs to NM32-2668(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Assessment of the area under serum concentration-time curve over dosing interval (AUCtau)(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Best Overall Response (BOR) according to RECIST 1.1(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed for up to 30 days following last dose of study treatment)
- Overall Response Rate (ORR) according to RECIST 1.1(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed for up to 30 days following last dose of study treatment)
- Assessment of clearance (CL) of NM32-2668 in serum(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Assessment of accumulation ratios of Cmin (ARcmin) of NM32-2668 in serum(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Assessment of accumulation ratios of AUC (ARauc) of NM32-2668 in serum(From date of randomization until end of treatment, assessed for up to 336 days (i.e., 12 treatment cycles) or through treatment discontinuation)
- Time to Response (TTR) according to RECIST 1.1(From date of randomization until the date of first documented treatment response according to RECIST 1.1)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.Neoplasms, Myelogenous Leukemia, AcuteNCT02098967Hoffmann-La Roche68
招募中
1 期
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsTumor, SolidMalignant NeoplasmMetastatic CancerAdvanced Solid TumorNon Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaCancerMelanomaLeiomyosarcomaLiposarcomaNCT05094804OncoResponse, Inc.172
已完成
1 期
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid TumorsAdvanced Solid TumorNCT05101109ABL Bio, Inc.24
已完成
1 期
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in RemissionLeukemia, Myeloid, AcuteNCT01632852CSL Limited30
招募中
1 期
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorsNCT06724016Hanmi Pharmaceutical Company Limited292